CSL Ltd Annual Report 2021

Cover	1
Chair and CEO message	4
2021 Performance	8
Business performance highlights	8
Financial highlights	9
Our Company	10
CSL at a glance	10
Our businesses	10
COVID-19: Our efforts	11
Our locations	12
Our product portfolio	13
Our research and development pipeline	13
Our Strategy and Performance	16
Our 2030 strategy	16
How we create value	18
United Nations sustainable development goals	20
Reported results	20
Our operating review	20
Our Material Risks	22
Patient safety and product quality	22
Product innovation and competition	22
Supply, capacity and operations	22
Market access	23
People and culture	23
Privacy and cybersecurity	23
Our Future Prospects	24
Business strategies, prospects and likely developments	24
Powered by Innovation	26
Expanding our R&D footprint	26
Our therapeutic areas	27
Our strategic scientifi c platforms	30
Focus on infl uenza vaccine technologies	30
Global collaborations for innovation	31
Strategic support for innovative medical research	31
Listening to out patients’ needs	32
Clinical trial improvements which will benefi t patients	32
Clinical trials in progress and new	32
Delivering innovative solutions to unprecedented challenges	33
New products to market	36
Global Reach and Impact	38
Commercial strength	38
Global reach and focus	38
Donor management	39
Focus on effi ciency, standardised manufacturing processes and integrated supply chain	40
Secure and reliable supply	40
Environment, health and safety	41
A Trusted Health Partner	45
Product quality and safety	45
Value and access	46
Public policy engagement	47
Infl uenza pandemic and emergency response	49
Relationships with patient groups	49
Responsible marketing and promotion	50
Privacy and cybersecurity	50
Ethical conduct	51
Promising Futures	52
Diversity, equity and inclusion (DE&I)	52
Encouraging, developing and celebrating the promise of our people	53
Safety and wellbeing	55
Our Communities	56
Our approach	56
Support for patient communities	57
Support for biomedical communities	58
Governance	62
Governance structure	62
Board composition	62
Board of Directors	63
Board committees	66
Leadership team	66
Ethics and transparency	68
Disclosure	68
Corporate governance	68
Risk management	68
Tax transparency	68
Financial Performance	69
Directors’ Report	70
Auditor’s Independence Declaration	75
Consolidated Statement of Comprehensive Income	108
Consolidated Balance Sheet	109
Consolidated Statement of Changes in Equity	110
Consolidated Statement of Cash Flows	111
Notes to the Financial Statements	112
Directors’ Declaration	150
Independent Auditor’s Report	151
Share Information	157
Key Performance Data Summary	159
Medical Glossary	160

Made with FlippingBook

RkJQdWJsaXNoZXIy MjE2NDg3